MedTrace Logo

Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer

NCT02885974 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2025-07-28

No results posted yet for this study

Summary

The purpose of this study is to compare patient tumor tissue before and after treatment with chemotherapy plus celecoxib. Investigators will look at gene expression, to see what effect celecoxib may have on tumor cells.

Conditions

Interventions

DRUG

Celecoxib

Celecoxib (100 mg daily)

DRUG

Gemcitabine

1,000 mg/m2 (IV), on Days 1 and 8 of each 21-day cycle. Up to 4 cycles.

DRUG

Cisplatin

70 mg/m2 (IV), on Day 1 of each 21-day cycle. Up to 4 cycles.

Sponsors & Collaborators

  • Baylor College of Medicine

    lead OTHER

Principal Investigators

  • Aihua Edward Yen, MD · Baylor College of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2024-03-31
Completion
2025-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02885974 on ClinicalTrials.gov